Aolin Wang
Education
Ph.D. and M.Sc., epidemiology, UCLA Fielding School of Public Health; B.Med., preventive medicine, Fudan University School of Public Health
Summary of Experience
Dr. Wang is an epidemiologist with expertise in epidemiologic methodology and advanced statistical techniques in health economics and outcomes research (HEOR). She has conducted comparative effectiveness studies; analyzed health care resource utilization and costs, treatment patterns, and clinical outcomes; and studied patient-reported outcomes (PROs). Dr. Wang has used data from large health insurance claims databases, clinical trials, medical chart review studies, hospital databases, and literature reviews to conduct HEOR assessments in oncology, hematology, cardiovascular disease, mental disorders, neurology, immunology, dermatology, and rheumatology. Her recent work includes real-world historical control studies to contextualize the results of single-arm trials and to convey meaningful value messages in health technology assessment (HTA) submissions and to regulatory agencies. She has presented her work at numerous conferences and published articles in a number of peer-reviewed journals. Prior to joining Analysis Group, Dr. Wang was a postdoctoral scholar at the University of California, San Francisco.
-
Delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation
American Heart Journal Plus, 2024
2024Luo X, Chaves J, Dhamane AD, Dai F, Latremouille-Viau D, Wang A
-
Delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation
American Heart Journal Plus: Cardiology Research and Practice, 2024
2024Luo X, Chaves J, Dhamane AD, Dai F, Latrémouille-Viau D, Wang A
-
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
Leukemia, 2022
2022Reiter A, Gotlib J, Álvarez-Twose I, Radia DH, Lübke J, Bobbili PJ, Wang A, Norregaard C, Dimitrijevic S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky IA, Perkins C, Sperr WR, Sriskandarajah P, Chin A, Sendhil SR, Duh MS, Valent P, DeAngelo DJ
-
MPN-435 Overall Survival in Patients With Systemic Mastocytosis With Associated Hematologic Neoplasm Treated With Avapritinib Versus Best Available Therapy
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Reiter A, Gotlib J, Álvarez-Twose I, Radia D, Lübke J, Bobbili P, Wang A, Norregaard C, Dimitrijević S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky I, Perkins C, Sperr W, Sriskandarajah P, Chin A, Sendhil S, Duh MS, Valent P, DeAngelo D
-
Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn's Disease: A Retrospective Claims Database Analysis
Crohn's & Colitis 360, 2022
2022Ungaro RC, Griffith J, Garcia-Horton V, Wang A, Cross RK
-
September 10, 2024
-
December 1, 2023
-
August 17, 2022